At the #CART22 meeting jointly run by EHA/EBMT, one of the sessions yesterday attracting a lot of interest and attention was one on the application of CAR T cell therapy beyond hematologic malignancies and solid tumours.

In a world where academic medicine is increasingly the domain of sub-specialists, as it is in many professions, it was refreshing to see the organizers of the meeting think ‘outside the box’ and offer the opportunity to hear speakers you wouldn’t typically expect at a meeting organized by hematology focused organizations.

Is the future of CAR T cell therapy, to paraphrase the oft-quoted Star Trek introduction, to seek new frontiers and boldly go where T cells have not gone before?

In this post we take a look at some of the data presented and offer our perspectives.

BSB readers can login to read more, or you can click here to find out more about purchasing access to BSB.

This content is restricted to subscribers

Posted by